<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004762</url>
  </required_header>
  <id_info>
    <org_study_id>199/11707</org_study_id>
    <secondary_id>SCRF-94304</secondary_id>
    <nct_id>NCT00004762</nct_id>
  </id_info>
  <brief_title>Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scripps Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical,
      radiologic, and histologic parameters in patients with early stage primary sclerosing
      cholangitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients are treated with subcutaneous injections of cladribine (2-chlorodeoxyadenosine;
      2-CdA) for 5 consecutive days every month for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1994</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>5</enrollment>
  <condition>Cholangitis, Sclerosing</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cladribine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Stage I-III primary sclerosing cholangitis

        Radiologically and pathologically documented

        No concomitant liver disease, e.g.:

          -  Viral hepatitis

          -  Autoimmune hepatitis

          -  Primary biliary cirrhosis

          -  Cirrhosis

          -  Portal hypertension or associated complications

          -  Jaundice caused by dominant stricture

        --Prior/Concurrent Therapy--

        No concurrent immunosuppressives

        --Patient Characteristics--

        Hematopoietic:

          -  Absolute neutrophil count at least 2500/mm3

          -  Platelet count at least 100,000/mm3

          -  Hemoglobin at least 10 g/dL

        Other:

          -  No active infection

          -  No fistula abscess

          -  No active inflammatory bowel disease

          -  Quiescent disease allowed, including: Chronic ulcerative colitis Crohn's disease

          -  No other significant immunologic disorder

          -  No active malignancy

          -  No active alcohol or drug abuse

          -  No pregnant or nursing women

          -  Effective contraception required of fertile patients

        Endoscopic retrograde cholangiopancreatography within 36 months prior to registration

        Liver biopsy within 12 months prior to registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J. Pockros</last_name>
    <role>Study Chair</role>
    <affiliation>Scripps Clinic</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>gastrointestinal disorders</keyword>
  <keyword>primary sclerosing cholangitis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

